Evidence map›Paper›PMID 35972896›Full record

ArticleJournal of medicinal chemistry2022

Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrofilaricidal Compounds for the Treatment of Human Filarial Infections.

Natalie Hawryluk, Dale Robinson, Yixing Shen, Graham Kyne, Matthew Bedore, Sanjay Menon, Stacie Canan, Thomas von Geldern, Simon Townson, Suzanne Gokool and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 5 countries.

Natalie HawrylukBristol Myers Squibb, San Diego, California 92121, United States.ORCID 0000-0002-8930-1533
Dale RobinsonBristol Myers Squibb, San Diego, California 92121, United States.
Yixing ShenBristol Myers Squibb, San Diego, California 92121, United States.
Graham KyneZoetis, Kalamazoo, Michigan 49001, United States.
Matthew BedoreZoetis, Kalamazoo, Michigan 49001, United States.
Sanjay MenonZoetis, Kalamazoo, Michigan 49001, United States.
Stacie CananBristol Myers Squibb, San Diego, California 92121, United States.
Thomas von GeldernEmbedded Consulting, Richmond, Illinois 60071, United States.
Simon TownsonNorthwick Park Institute for Medical Research, London HA1 3UJ, UK.
Suzanne GokoolNorthwick Park Institute for Medical Research, London HA1 3UJ, UK.
Alexandra EhrensInstitute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Marianne KoschelInstitute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Nathaly Lhermitte-VallarinoUnité Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR 7245), Muséum national d'Histoire Naturelle, Paris 75005, France.
Coralie MartinUnité Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR 7245), Muséum national d'Histoire Naturelle, Paris 75005, France.
Achim HoeraufInstitute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Geraldine HernandezBristol Myers Squibb, San Diego, California 92121, United States.
Deepak DalvieBristol Myers Squibb, San Diego, California 92121, United States.
Sabine SpechtInstitute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Marc Peter HübnerInstitute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Ivan ScandaleDrugs for Neglected Diseases Initiative, Geneva 1204, Switzerland.
Bristol-Myers Squibb (United States) · USUniversity Hospital Bonn · DEZoetis (United States) · USDrugs for Neglected Diseases Initiative · CHMolécules de Communication et Adaptation des Micro-organismes · FRNorthwick Park Institute for Medical Research · GBEmbedded Systems (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastating of all tropical diseases, affecting about 145 million people worldwide. Efforts to control and eliminate onchocerciasis are impeded by a lack of effective treatments that target the adult filarial stage. Herein, we describe the discovery of a series of substituted di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as novel macrofilaricides for the treatment of human filarial infections.

Indexed as

Elephantiasis, FilarialOnchocerciasisAdultAminesHumansAmines

Identifiers

PMID35972896
PMCPMC9421654
OpenAlexW4291993570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.